Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children’s Oncology Group Study

PURPOSE: Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor. The purpose of this study was to determine the recommended phase 2 dose, pharmacokinetics, pharmacodynamic effects, and preliminary anti-tumor activity of sunitinib in a pediatric population. EXPERIMENTAL DESIGN: Patien...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: DuBois, Steven G., Shusterman, Suzanne, Ingle, Ashish M., Ahern, Charlotte H., Reid, Joel M., Wu, Bing, Baruchel, Sylvain, Glade-Bender, Julia, Ivy, Percy, Grier, Holcombe E., Adamson, Peter C., Blaney, Susan M.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3149978/
https://ncbi.nlm.nih.gov/pubmed/21690570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0237
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki